DNA Diagnostics Market Size Worth USD 31.31 billion by 2034 | CAGR: 9.3%

The global DNA diagnostics market size is expected to reach USD 31.31 billion by 2034, according to a new study by Polaris Market Research. The report “DNA Diagnostics Market Size, Share, Trends, Industry Analysis Report: By Offering (Instruments, Reagents & Kits, and Services & Software), Technology, Specimen, Application, End User, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) – Market Forecast, 2025 - 2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The expansion of the DNA diagnostics market is being driven by the rising prevalence of genetic disorders worldwide. The World Health Organization (WHO) estimated that there are around 10,000 different types of monogenic diseases caused by mutations in a single gene. The global prevalence rate is approximately 10 per 1000 individuals, indicating that between 70 million and 80 million people are affected by genetic disorders. This surge in genetic conditions has created an increased demand for efficient tools to detect and evaluate genetic disorders. Consequently, the growing incidence of rare genetic diseases, hereditary cancers, and inherited metabolic disorders is propelling the advancement of diagnostic technologies, thereby stimulating the DNA diagnostics market.

The market for DNA diagnostics is experiencing significant growth due to the advancements in genomic technology, which have improved the accuracy, speed, and affordability of genetic testing. For instance, in May 2024, BioAro, a genomic research and technology company, launched PanOmiQ, a software that provides real-time insights into the complexities of the human genome. These types of technological enhancements facilitate in-depth genome analysis, resulting in more detailed and dependable diagnostic outcomes. Thus, the ongoing evolution of genomic technologies is driving the growth of the DNA diagnostics market by supporting the development of new diagnostic tools and methods.

Do you have any questions? Would you like to request a sample or make an inquiry before purchasing this report? Simply click the link below: https://www.polarismarketresearch.com/industry-analysis/dna-diagnostics-market/request-for-sample

Healthcare firms are escalating their financial investments to drive innovation, research, and the advancement of new diagnostic technologies. These investments are empowering companies to progress genomic research, refine testing methodologies, and enhance the precision and dependability of DNA diagnostics. Consequently, company investments are accelerating collaborations with research institutions and the integration of genetic testing into healthcare practices, thereby stimulating the expansion of the global DNA diagnostics market.

DNA Diagnostics Market Report Highlights

• The reagents and kits segment is expected to grow with a substantial CAGR in the global market, driven by the development of comprehensive suites tailored for genetic testing.
• In 2023, the cancer genetics tests segment accounted for the largest market share because of the increasing prevalence of cancer globally.
• In 2023, North America dominated the global DNA diagnostics market in terms of revenue due to the presence of well-established institutions and a robust healthcare infrastructure in the region.
• The DNA diagnostics market in China is expected to grow substantially because of the country's increasing investment in biotechnology and healthcare infrastructure.
• The global key market players are Abbott; Agilent Technologies, Inc.; Avalon GloboCare Corp.; Beckman Coulter, Inc.; Bio-Rad Laboratories, Inc.; Cepheid; F. Hoffmann-La Roche Ltd; GE HealthCare; Hologic, Inc.; Illumina, Inc.; QIAGEN; Siemens Healthcare Private Limited; and Thermo Fisher Scientific Inc.

Polaris Market Research has segmented the DNA diagnostics market report based on offering, technology, specimen, application, end user, and region:

By Offering Outlook (Revenue - USD Billion, 2019 - 2032)

• Instruments
• Reagents & Kits
• Services & Software

By Technology Outlook (Revenue - USD Billion, 2019 - 2032)

• In Situ Hybridization
• Mass Spectroscopy
• Microarrays
• Polymerase Chain Reaction (PCR)
• Sequencing
• Others

By Specimen Outlook (Revenue - USD Billion, 2019 - 2032)

• Blood, Serum, and Plasma
• Urine
• Others

By Application Outlook (Revenue - USD Billion, 2019 - 2032)

• Cancer Genetics Tests
• Infectious Diseases DNA Testing

• CT/NG Diagnostic
• HBV Diagnostic
• HCV Diagnostic
• HIV Diagnostic
• HPV Diagnostic
• MRSA Diagnostic
• TB Diagnostic
• Others

• Newborn Genetic Screening
• Preimplantation & Reproductive Diagnosis
• Non-Infectious Diseases DNA Testing

• Cardiovascular Diseases
• CNS & PNS Related
• Lung, Kidney, Liver & GT Related
• Sensory Diseases
• Skeletal, Connective, Ectodermal & Dermal DNA Testing

• Hematology & Immunology/Identity Diagnostics & Forensics
• Pharmacogenomics/Drug Metabolism
• Prenatal DNA Carrier Screening
• Others

By End User Outlook (Revenue - USD Billion, 2019 - 2032)

• Diagnostic laboratories
• Hospitals & clinics
• Others

By Regional Outlook (Revenue - USD Billion, 2019 - 2032)

• North America

• US
• Canada

• Europe

• Germany
• UK
• France
• Italy
• Spain
• Russia
• Netherlands
• Rest of Europe

• Asia Pacific

• China
• India
• Japan
• South Korea
• Indonesia
• Malaysia
• Australia
• Rest of APAC

• Latin America

• Argentina
• Brazil
• Mexico
• Rest of Latin America

• Middle East & Africa

• UAE
• Saudi Arabia
• Israel
• South Africa
• Rest of MEA